

**183th Business Plan Presentations Held on December 13, 2016
at Iwasaki Gakuen, Shin-Yokohama, Japan**

1. TAOS Institute, Inc. President Dr. Tiejun Miao <http://www.taos.tokyo/index.html> (Japanese)

Established in September 2012 Capital stock: USD \$ 100,000

Taos Institute, Inc. is in possession of excellent sensor technology and leading-edge chaos analysis technology. Applying the fruits of basic research to date in various fields, its objective is to provide products and services of genuine use in modern living and industry, and thereby contribute to human health, both physical and mental, and a bright future. Its original technology for chaos forecasting and analysis captures the chaos (= a slightly fluctuating modulation or irregularity) found in bioactivity and natural phenomena. Through this technology, it can obtain advance knowledge of physical and mental changes, and thereby make a contribution to better health. Furthermore, it also offers chaos solutions, mainly to commercial enterprises.

- * Business in health prediction
- * Business in measurement and analysis of physical and mental health
- * Business in chaos solutions

【Re-Cap】 The presenter said that the company's name is a combination of "tao" (Chinese for "road" or "way") and the "chaos" of chaos analysis. It symbolizes their aspiration to "show the way through chaos analysis." In more specific terms, Taos is engaged in development areas such as vascular function inspection equipment designed for widespread diffusion in Japan, next-generation remote nursing and related systems enabling detection of irregularity and premonitory signs, systems for health forecasting and monitoring based on detection of quality of sleep by means of Sleep Health, and systems for measuring stress, fatigue, and tension with the Vital Hat pulse-wave measurement unit. These technologies reportedly make it possible to ascertain even the exact pathological change in the patient.



2. GeneCare Research Institute Co., Ltd. President Mr. Naoya Takahashi

<http://www.genecare.co.jp/en/index.html>

Established in December 2000 Capital stock: USD \$ 100,260

1) Business

* Development of the nucleic acid anti-cancer agent RECQL1-siRNA, which is designed to address as yet unmet medical needs and has few side effects

2) Features

* The anti-cancer agent being developed by the company selectively kills or injures cancer cells with virtually no influence on normal cells.

* Testing with model mice with peritoneal metastasis of ovarian cancer that is resistant or had acquired resistance to conventional anti-cancer agents as well found a significant life-prolonging effect, with virtually no side effects.

3) Future activities

* Start of consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) on the road to clinical development

-- Preliminary meeting (early December 2016) followed by face-to-face advice (tentatively in the spring of 2017)

-- The initial target is peritoneal metastasis of recurrent ovarian cancer (ascites retention), which cannot be treated with conventional anti-cancer agents. The company is making preparations for physician-led clinical trials under the guidance of Dr. Keiichi Fujiwara, Professor of the Saitama International Medical Center attached to Saitama Medical University. For this purpose, it first must obtain competitive public financing. It is also researching adaptability for other types of cancer inducing ascites retention, such as cancer of the digestive tract.

【Re-Cap】 The term "unmet medical needs" refers to domains that have been neglected by drug companies, with diseases whose patients are awaiting cures, because there are no effective pharmaceuticals in them at present. Thus far, the standard for alleviation of patient pain and distress has rested on the extent of tumor shrinkage or prolongation of life. Now, however, attention is focusing on improvement of the quality of life (QOL) for patients through "palliative care." The company's drugs reportedly have almost no side effects, and can dramatically improve QOL for patients. The presenter said it is also looking to initial public offering as a prospect further in the future.



3. ReproM., Inc. President Dr. Hiromitsu Tanaka <https://www1.niu.ac.jp/reprom/about/> (Japanese)

Established in March 2016 Capital stock: USD \$ 20,000

The members of ReproM., Inc. have been pursuing genetic analysis concerning the process of sperm formation. According to reports in recent years, about one in every five couples struggles with infertility. Public support is being provided for treatment of infertility also in Japan, which is experiencing falling birthrates and population aging. This year, they decided to go into business so that the results of their research could benefit society. This business revolves around supplements to increase the rate of successful conception. The members realized there were prospects for easy and low-cost provision of these supplements in the form of lozenges and tablets in sales of ingredients derived from glycyrrhiza, a crude drug whose safety has been established. This product has no parallels and has already been patented. The company has also begun testing use for artificial insemination of livestock, and is selling food products to support conception among humans and animals.

【Re-Cap】 Glycyrrhiza contains glycyrrhizin, which is an important constituent. The company extracts this ingredient for use in the crude drug. According to Mr. Tanaka, its president, glycyrrhiza also contains isoliquiritigenin and formononetin, and the company discovered that these constituents help to activate sperm and are useful for treatment of infertility. If there emerge drugs that can be taken like supplements or drunk like beverages, they will presumably experience rapid diffusion as effective means of treating infertility.



《Impressions》 This was the last business plan presentation meeting of this year, and it had a good turnout. We hope all of you will continue to watch our activities, because the meetings are attracting a steady stream of companies desiring to make presentations. We are eagerly looking forward to deepening our ties with all of you next year, and although it is a little early, we wish you a happy holiday season!